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from group IID, but TIBC (734 6 76) remained significantlyChronic peritoneal dialysis in iron-deficient rats with solutions
higher than that in the group IID. Peritoneal iron deposits werecontaining iron dextran.
not detected. The morphometric analysis of the submesothelialBackground. We evaluated the effects of different concen-
space did not reveal any difference in thickness between dialysistrations of iron dextran administered through the intraperito-
groups. PETs were not significantly different among groups.neal route, in iron-deficient rats, on hematocrit (Hct in percent-
Conclusions. Intraperitoneal iron dextran supplementationage), serum iron (mg/dL), total iron binding capacity (TIBC
in concentrations of 2 mg/L of dialysis solution is nontoxic toin mg/dL), and the function and histology of the peritoneal
the peritoneum and effective in correcting iron deficiency inmembrane.
rats maintained on an iron-deficient diet. Iron dextran in con-Methods. Seventy-two male Sprague-Dawley rats weighing
centration of 1 mg/L of dialysis solution may be sufficient for85 to 110 g were divided into two groups and seven subgroups.
correcting a lesser degree of iron deficiency.Group I consisted of rats on iron-deficient chow, and group II
consisted of rats on normal chow. Both groups contained dial-
ysis control subgroups (N 5 12: IA, IID), dialyzed with Dia-
nealt solution, and tissue control subgroups (N 5 6: IE, IIN), in Anemia is a major and predictable complication ofwhich rats were not dialyzed and catheters were not implanted.
chronic renal failure. When end-stage renal disease (ESRD)Study group I contained the following study subgroups (N 5
evolves, the anemia is frequently severe and often im-12): (B) rats dialyzed with Dianealt solution containing 2 mg/L
of iron dextran and (C) rats dialyzed with Dianealt solution pairs rehabilitation despite adequate dialysis. Traditional
containing 1 mg/L of iron dextran. Group IID was dialyzed thinking has ascribed the anemia of chronic renal failure
with Dianealt solution containing 2 mg/dL of iron dextran. into four mechanisms: erythropoietin (EPO) deficiencyStudy duration was 12 weeks with peritoneal equilibration tests
[1, 2], shortened red cell survival [3–5], retained inhibi-(PETs) performed at baseline, 6 weeks, and 12 weeks. Prior
tors or toxic metabolites that inhibit erythropoiesis [6–9],to baseline, rats were placed on iron-deficient chow or normal
chow for three weeks. Dialysis was performed with three 25 mL and blood loss resulting from qualitative platelet defect
volume exchanges per day. Hematocrit (Hct), serum iron (Fe), present in uremia [10]. EPO deficiency is unquestionably
and total iron binding capacity (TIBC) were determined for a major mechanism of anemia. In the 1950s, the erythro-each study interval. After the final PET, the animals were
poietic effect of EPO was described, and the kidney wassacrificed, and the peritoneal membrane was evaluated by gross
found to be its source [11]. In the early 1980s, purifiedinspection and light microscopy.
Results. Rats on an iron-deficient diet developed severe iron- human EPA (rHuEPO) was synthesized, and the first clin-
deficiency anemia after three weeks of the diet (Hct 27; Fe 21 ical trial began in Seattle in 1985 [12]. The use of rHuEPO
to 23; TIBC 799 to 806). After 12 weeks, the rats remained has been a major advance in the treatment of anemia ofanemic in groups A (Hct 34 6 0.9; Fe 16 6 2; TIBC 998 6
chronic renal failure, but is associated with a twofold27) and IE (Hct 38 6 2.7), whereas the rats corrected anemia
increase in the requirement of iron [13]. For patientsin group B (Hct 45.8 6 1.8; Fe 115 6 15; TIBC 546 6 77).
The results were not significantly different from those of group ESRD, dietary iron is usually not sufficient to maintain
IID (Hct 47.1 6 1.6; Fe 94 6 19; TIBC 516 6 46). In group the iron body stores, and hence, these patients frequently
C, Hct (44.8 6 2.1) and Fe (94 6 19) did not differ significantly develop functional iron deficiency [14]. The most impor-
tant cause of resistance to EPO therapy has been attrib-
uted to the presence of inadequate available iron. Thus,Key words: anemia, chronic renal failure, end-stage renal disease, ade-
quate dialysis, red blood cells, erythropoietin. long-term replacement therapy is required to maintain
adequate available iron during EPO treatment [15].Received for publication May 9, 2000
Peritoneal dialysis patients seem to be less prone toand in revised form August 9, 2000
Accepted for publication August 21, 2000 iron deficiency than hemodialysis patients [16]. In pa-
tients on hemodialysis, blood losses are mainly causedÓ 2001 by the International Society of Nephrology
764
Reddy et al: Dextran in iron-deficient rats 765
by dialysis, venipuncture, and gastrointestinal bleeding. hematocrit and serum iron. A search of the literature
showed no previous study focused on iron deliveryThis may amount to 6 L per year [17]. Even though
patients on peritoneal dialysis (PD) are less prone to through the intraperitoneal route in iron-deficient rats.
The goal of the present study was to evaluate the effectsiron deficiency, they do require iron supplementation to
compensate for losses of blood through the gastrointesti- of different concentrations of iron dextran administered
through the intraperitoneal route in iron-deficient ratsnal tract, menstruation, and laboratory sampling [18].
Dietary absorption of iron in peritoneal dialysis also and to evaluate the effects on hematocrit, serum iron,
and total iron binding capacity (TIBC). In addition,seems to be impaired [19]. The available routes of iron
delivery are intravenous and intramuscular injections membrane function and the histology of the peritoneal
membrane were to be evaluated.and oral administration. Oral administration depends
on patient compliance, gastrointestinal side effects, and
interactions with food and other medications [15]. The
METHODS
intravenous therapy in patients on continuous ambula-
Animals and treatmenttory peritoneal dialysis seems to be inconvenient because
of the nonavailability of an access and also the possibility This study was carried out in accordance with all of
the rules and regulations of the Animal Welfare Actof anaphylactic reactions [20–22]. The intramuscular in-
jections have been associated with the development of and was approved by the University Animal Care and
Use Committee. Animals were maintained and studiessarcomas at the injection sites [23, 24]. Because of the
complications of these routes, iron delivery through the carried out in an Association for Assessment and Ac-
creditation for Laboratory Animal Care Internationalintraperitoneal route provides an excellent alternative
to patients on peritoneal dialysis. The important factor (AALAC)–accredited facility.
Seventy-two male, nonuremic Sprague-Dawley ratswould be to determine the dosage required to maintain
the iron stores and also not to cause any deleterious were divided into two main groups and seven subgroups.
Group I (4 subgroups) consisted of rats on iron freeeffects to the peritoneal membrane. In the future, long-
term studies are required to evaluate the effects of intra- chow, and group II (3 subgroups) consisted of rats on
normal chow. Under group I, there were two studyperitoneal iron.
Our previous studies in rats have shown that there is groups and two control groups: (B; N 5 12) rats dialyzed
with Dianealt solution containing 2 mg/L iron dextran;absorption of more than 70% of iron dextran in a six-
hour cycle from the peritoneal cavity. This study also (C; N 5 12) rats dialyzed with Dianealt solution con-
taining 1 mg/L iron dextran; (A; N 5 12), a dialysisshowed that there were no signs of acute toxicity to
the peritoneal membrane, and no allergic manifestations control group; and (E, N 5 6) a tissue control group, in
which the rats were not dialyzed and catheters were notwere noticed [25, 26]. A six-month chronic dialysis study
was performed delivering 25 mL of dialysis solution per implanted. Under group II, there was one study group
and two control groups: (F; N 5 12) rats dialyzed withday for a period of six months. The solutions contained
iron dextran in concentrations of 2 mg and 10 mg/L. This Dianealt solution containing 2 mg/L iron dextran; (D;
N 5 12) a dialysis control group, and (N; N 5 6) a tissuestudy showed not only an increase in serum iron and
hematocrit levels, but also showed peritoneal deposits control group, in which the rats were not dialyzed and
catheters were not implanted.of iron and alteration of membrane function tests in rats
that were exposed to high-dose iron. The differences The rats in Group I were housed in specially made
plastic cages. They were different from the normal cagesbetween the high- and low-dose groups led to the conclu-
sion that iron deposition is dose dependent [27]. Pecoits in that they had a raised plastic grate two to three inches
above the bottom instead of the bedding as present inet al studied the influence of iron dextran intraperitoneal
administration on the function and histology of the peri- the normal cages. The cages were changed on a daily
basis to maintain sanitation and dryness. These plastictoneum in rats undergoing chronic peritoneal dialysis
[28]. The rats were dialyzed with solution containing iron grates were used to prevent the rats from eating the
bedding that was thought to be a potential source ofdextran in concentrations of 0.5, 0.25, and 0.125 mg/L.
The authors concluded from this study that there is a iron. Upon arrival, rats in Groups A, B, C, and E of
Group I were placed on iron-free chow, and rats inhigher permeability to small solutes after long-term PD
I rats. They also showed the absence of iron deposition Groups D, F, and N in Group II were placed on normal
chow for the duration of the study, and the time wason the peritoneal membrane when dialyzed with fluids
containing iron dextran. designated as minus three weeks. The rats weighed be-
tween 85 and 110 g on arrival at four weeks of age. TheAll of the previously mentioned studies were carried
out in normal, non–iron-deficient rats. The next step was rats of this weight and age were used for this study
because of the high requirement of iron at this age. Into administer iron dextran through the intraperitoneal
route in iron-deficient rats and to study the effects on our preliminary unpublished studies, we used rats that
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were eight weeks old weighing between 275 and 300 g. procedure was performed carefully to avoid bleeding and
In order to make these rats iron deficient, long periods trauma to the peritoneum. The hole into the peritoneum
of time on iron-free chow were required as the external was large enough to allow the catheter to pass but small
requirement of iron in these rats is considerably less enough that the catheter fitted snugly. With the use of
when compared with the younger rats [29]. Catheter a 3 mm trocar, the other end of the catheter was tunneled
implantation was done in Groups A, B, C, D, and F two under the skin to a point between the animal’s scapulas
weeks after arrival. One week after catheter implanta- that had been shaved and disinfected. The trocar was
tion, a baseline peritoneal equilibration test (PET) was then forced through the skin and the catheter pulled
performed and was designated as time zero. A mid-term through the tunnel. When the second cuff was next to
PET was performed at 6 weeks, and a final PET was the exit hole, the catheter was trimmed leaving approxi-
performed at 12 weeks. All exchanges following the base- mately 1.5 to 2.0 cm exposed. The catheter was then
line PET in Groups B, C, and F contained iron dextran capped. The animals were allowed to wake up, placed
(InFeD; Schein Pharmaceutical, Phoenix, AZ, USA) for again in their cages, and allowed free access to food and
the duration of the study. The iron dextran contains 5% water. The animals were given bupremorphine subcuta-
iron and 20% dextran. The ultrastructure comprises a neously for analgesia with the dose adjusted as needed.
central FeOOH core and dextran chains attached to the This therapy was continued for 72 hours after the surgery
central core. The molecular weight of the iron dextran and as necessary. Antibiotics (vancomycin 120 mg/L and
complex was between 160 and 180 kD [30]. The iron gentamicin 32 mg/L) were given postoperatively, intra-
dextran was available in 2 mL ampules containing 50 mg peritoneally until the fifth day and then discontinued.
of elemental iron per milliliter. Iron dextran was added
to 1 L bags of PD solution (Dianealt; Baxter Healthcare, Dialysis exchanges
Deerfield, IL, USA) and mixed well to give the following Dialysis started immediately following surgeries with
concentrations of elemental iron: 1 mg/L for the C Group, the instillation volume gradually increased from 15 to
2 mg/L for the B Group, and 2 mg/L for the F Group. 25 mL over a period of one week. During the first week,
The rationale for the selection of iron dextran concentra- the animals were dialyzed with standard 1.5% Dianealt
tion was based on the desired delivery of iron from the solutions without added iron. Dialysis exchanges were
peritoneal cavity in PD patients. Assuming the use of performed three times a day at 0800, 1400 and 2200 hours,
10 L of dialysis solution per day and 70% absorption, seven days per week, for 12 weeks according to the fol-
1 mg/L will deliver 10 mg of iron and at least 7 mg will lowing technique. The catheter was uncapped, and the
be absorbed, and in case of 2 mg/L, at least 14 mg will be
remaining solution was drained. The tip of the catheter
absorbed. Considering the lower requirements of PD
was soaked with 3% Amukin, and the dialysis solutionpatients, the doses are sufficient to maintain the iron
was injected through the catheter using a 30 mL syringestores. In addition to this, toxicity can also be monitored.
and a sterile connection; a sterile metal cap was replaced.The incorporation of iron dextran into the dialysate did
Dianealt 1.5% was used for the day dialysis and Dia-not change the color of the dialysate when the concentra-
nealt 4.25% for the night. On the eighth day, iron wastion was 1 mg/L, but a slight change in color was observed
added to the different solutions as described in the previ-when the concentration was 2 mg/L. A 25 mL aliquot of the
ous section. From this day on, prophylactic antibioticssolution was then drawn from the warm bag and infused
were started. The antibiotic schedule changed every fiveinto the animal through a chronic peritoneal catheter.
days according to the sequence: ceftazidime, 125 mg/L;
gentamicin, 8 mg/L; ciprofloxacin, 25 mg/L; sulfamethox-Catheter implantation
azole/trimethoprim 200, 40 mg/L; vancomycin, 25 mg/L.The animals were anesthetized and maintained on
The rationale for the cyclic antibiotic schedule was toisoflurane utilizing the Hallowell Anesthesia Worksta-
avoid bacterial resistance [31]. Samples of dialysate fortion (Hallowell EMC, Pittsfield, MA, USA). The abdo-
culture were collected three times per week, before themen was shaved and disinfected with Amukin (Amuch-
instillation of the morning fresh dialysis solution.ina, Genova, Italy). The area was then covered with
Tegadermt (3M Healthcare, St. Paul, MN, USA). An
Peritonitisincision was made in the skin along the midline starting
Diagnosis of peritonitis was based only on the cultureat the xiphoid process and extending caudally approxi-
results, because unlike in humans, there is no acceptedmately 3 cm. A blunt dissection was then done on the
definition of peritonitis based on the white cell count inmidline through the abdominal wall approximately 1.5
the rat. Upon diagnosis of peritonitis (more than 10 col-to 0.75 cm below the xiphoid process. Once the cavity
onies on the agar plate), the animals were treated withwas penetrated, the tip of the catheter was advanced
vancomycin (120 mg/L) and gentamicin (32 mg/L) untilinto the cavity and secured with a single stitch through
the cuff material and the superficial muscle layer. The the culture turned negative usually within 48 hours.
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Table 1. Changes in weights and hematocrits at 23 weeks andPeritoneal membrane function and blood tests
statistical analysis
The peritoneal membrane function was assessed by per-
23 Weeks Mean6SDforming a one-hour PET using 1.5% dextrose PD solu-
Group A Weight 97.1164.08tions. A dextrose concentration of 1.5% was used for an
Hct 36.3361.55
overnight exchange before the PET. PET was done Group B Weight 97.3564.80
Hct 35.9161.16on the 8th day, at 6 weeks, and at 12 weeks. At time
Group C Weight 85.4968.89zero, 25 mL of dialysis solution were instilled. Then at
Hct 34.1161.36
one hour, the animals were anesthetized, and a sample Group D Weight 85.0367.34
Hct 35.3061.25of dialysate was taken for urea nitrogen and glucose.
Group F Weight 85.2868.74Immediately thereafter, a blood sample (2 to 3 mL)
Hct 35.7261.55
was taken by direct cardiac puncture for urea nitrogen, Group E Weight 104.40612.12
Hct 35.2162.3glucose, hematocrit, serum iron, TIBC, and hemoglobin.
Group N Weight 105.8616.22In the case of peritonitis, the test was deferred until the
Hct 35.6662.07
cultures were negative. Peritoneal membrane transport
No significant differences were seen between the different groups.
was quantitated by the dialysate to plasma ratio (D/P) Abbreviations are: IFC, iron free chow, and NC, normal chow. Group A,
IFC 1 normal dialysis; Group B, IFC 1 2 mg/L iron; Group C, IFC 1 1 mg/Lof urea nitrogen and D/D0 of glucose, where D is the
iron; Group D, NC 1 normal dialysis; Group F, NC 1 2 mg/L iron; Group E,
glucose concentration in the dialysate after one-hour IFC, no dialysis, no catheter; Group N, NC, no dialysis, no catheter.
dwell, and D0 is glucose concentration in the dialysis
solution before instillation into the peritoneal cavity.
High D/P and low D/D0 ratios indicate higher transport;
assessed by one-way analysis of variance (ANOVA), withlow D/P and high D/D0 indicate low transport.
Tukey’s correction for multiple comparisons using Sig-Weight. All of the animals were weighed once weekly
maStat 2.0 (SPSS Inc., Chicago, IL, USA) for Windows.before the morning dialysis exchange.
Differences were considered significant at a P , 0.05.The last exchange. After the final blood sample was
taken, a sample of fluid was taken through the catheter.
The abdomen of the animal was then opened, and the RESULTS
solution was completely drained; samples of the perito- Sixty-six of the 72 rats completed the study. Three rats
neal membrane were taken from the abdominal wall, in Group C, two rats in Group D, and one rat in Group
liver, and the mesentery of the small intestine. The mem- F were excluded from the study because of catheter
brane was evaluated by gross inspection and light micros- malfunction. There were no complications caused by
copy. Prussian blue staining was used to detect iron depo- cardiac punctures. Tables 1 and 2 show all the parameters
sition in the peritoneum in all tissue samples. Gomori’s monitored.
trichrome staining was used to determine the degree of
fibrosis in the submesothelial space of the abdominal Body weight
wall. The procedure differentially stained connective tis- Changes in body weight are shown in Figure 1. The
sue elements as follows: collagen, green; muscle tissue, starting weights of all rats were between 85 and 110 g,
red; and nuclei, blue to black. The thickness of the sub- with no significant difference in the weights of rats upon
mesothelial space was calculated from 10 different mea- arrival (23 weeks). At baseline, significant differences
surements in each specimen, using a special scale applied were seen in weights of rats in the iron-deficient group
over a microscopic field as described by Frazier-Jessen (Group I) when compared with the rats in the non–iron-
and Kovacs [32]. deficient group (Group II). When compared with the con-
Animals were terminated and excluded from the study trol, animals on dialysis manifested a diminished weight
in cases of catheter malfunction. In malfunctioning cathe- gain, which was not significant. In Group I, at 6 and 12
ters, the fluid could be neither infused nor drained (two- weeks, the groups that were given intraperitoneal iron
way obstruction). Wrapping of internal end of the catheter had an increased weight gain when compared with the
by the omentum usually brought about catheter malfunc- dialysis control. The group dialyzed with 2 mg/L iron dis-
tion. played an additional weight gain when compared with rats
Laboratory tests. Urea nitrogen and glucose were de- dialyzed with 1 mg/L iron. These differences in weights
termined on a CX5-CE clinical chemistry analyzer (Beck- were not statistically significant at 6 and 12 weeks.
man Instruments, Brea, CA, USA).
Hematocrit
Statistical analysis Changes in hematocrit over time are shown in Figure
All data are presented as mean 6 SD. Statistical analy- 2. There were no significant differences in hematocrit in
all the animals upon arrival (23 weeks). At baseline,sis of values at different time points among groups were
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Table 2. Changes in weights, hematocrits, serum iron and TIBC at 0, 6 and 12 weeks and statistical analysis
0 weeks 6 weeks 12 weeks Group A Group B Group C Group D Group F Group E Group N
mean 6 SD 0 6 12 0 6 12 0 6 12 0 6 12 0 6 12 0 6 12 0 6 12
Group A Weight 206.23 6 9.67 328.15 6 20.29 372.64 6 33.23 a b b b b c a b b
Hct 27.25 6 3.46 31.83 6 2.44 34.08 6 0.9 a a a a a a a a a a a a a
S. iron 23 6 4.71 20.17 6 3.07 16.17 6 2.04 b b b b b b b b b b
TIBC 806.25 6 51.63 894.45 6 26.27 998 6 27.05 a a a a a a a a a a
Group B Weight 209.18 6 9.48 355.28 6 16.27 423.13 6 14.07 a a a b b
Hct 27.66 6 2.67 37.91 6 3.45 45.83 6 1.80 a a a a a a a a a a a
S. iron 27.41 6 6.73 56.93 6 7.82 115 6 15.11 b b b b b
TIBC 804.42 6 52.76 796.83 6 45.80 546.83 6 77.50 a a a a a a a
Group C Weight 201.3 6 8.50 333.03 6 43.44 414.39 6 30.78 a b a a b b
Hct 27.44 6 1.87 37.44 6 3.16 44.77 6 2.10 a a a a a a a a a a
S. iron 21 6 5.97 40.78 6 2.28 94 6 18.94 b b b b b b
TIBC 799.10 6 112.9 800.25 6 60.03 733.89 6 75.69 a a a a a a a a a
Group D Weight 220.37 6 12.42 410.75 6 24.03 462.78 6 28.32 a b b a a b
Hct 41.60 6 2.22 44.30 6 1.16 47.10 6 1.59 a a a a a a a a a a a
S. iron 220.4 6 55.39 203.62 6 10.44 161.7 6 26.14 b b b b b b b
TIBC 571 6 87.59 522.30 6 44.39 516.20 6 46.09 a a a a a a a a
Group F Weight 214.79 6 11.89 396.33 6 41.33 458.78 6 38.67 b b
Hct 41.36 6 1.85 44.27 6 3.61 47 6 2.18 a a a a a a a a a a a
S. iron 235.2 6 68.34 207 6 22.05 161.40 6 41.63 b b b b b b
TIBC 530.43 6 46.68 511.36 6 48.30 495.40 6 85.89 a a a a a a a a
Group E Weight 226 6 8.74 352.68 6 14.27 417.53 6 11.65 c a a a b
Hct 27.11 6 2.3 33.23 6 1.97 38.63 6 2.68 a a a a a a a a a a a a
Group N Weight 250.63 6 4.97 425.57 6 13.57 513.55 6 8.41 a b b a b b a b b a a b
Hct 43 6 1.57 47.46 6 1.74 50.80 6 1.01 a a a a a a a a a a a a a a
Groups are defined as: IFC, iron free chow, NC, normal chow; Group A, IFC 1 normal dialysis; Group B, IFC 1 2 mg/L iron; Group C, IFC 1 1 mg/L iron;
Group D, NC 1 normal dialysis; Group F, NC 1 2 mg/L iron; Group E, IFC, no dialysis, no catheter; Group N, NC, no dialysis, no catheter.
a P , 0.001, b P , 0.05, c P 5 0.004
Fig. 1. Changes in weight over time. Abbreviations are: IFC, iron- Fig. 2. Changes in hematocrit over time. Abbreviations are: IFC, iron-
deficient chow; NC, normal chow. Symbols are: (circle) Group A, IFC 1 deficient chow; NC, normal chow. Symbols are: (circle) Group A, IFC 1
normal dialysis; (inverted triangle) Group B, IFC 1 2 mg/L iron; (hexa- normal dialysis; (inverted triangle) Group B, IFC 1 2 mg/L iron; (hexa-
gon) Group C, IFC 1 1 mg/L iron; (square) Group D, NC 1 normal gon) Group C, IFC 1 1 mg/L iron; (square) Group D, NC 1 normal
dialysis; (triangle) Group F, NC 1 2 mg/L iron; (diamond) Group E, dialysis; (triangle) Group F, NC 1 2 mg/L iron; (diamond) Group E,
IFC 1 no dialysis, no catheter; (1) Group N, NC 1 no dialysis, no IFC 1 no dialysis, no catheter; (1) Group N, NC 1 no dialysis, no
catheter; *P , 0.001 (A vs. D); **P , 0.05 (A vs. D); †P , 0.001 catheter; #P , 0.001 (A vs. B); **P , 0.001 (A vs. C); †P , 0.001
(C vs. D). (B vs. D); *P , 0.001 (C vs. D); ‡P , 0.001 (N vs. D).
of iron-deficient group (Group I). The rats on intraperi-
there were significant differences seen in the iron-defi- toneal iron had a higher hematocrit level when compared
cient group (Group I) when compared with the rats in with the dialysis control in the same group, and signifi-
the non–iron-deficient group (Group II). There were no cant differences were seen both at 6 and 12 weeks when
compared with the dialysis control (A). There were sig-significant differences seen at baseline in the subgroups
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Fig. 4. Changes in serum iron over time. Abbreviations are: IFC, iron-
deficient chow; NC, normal chow. Symbols are: (circle) Group A, IFC 1
normal dialysis; (inverted triangle) Group B, IFC 1 2 mg/L iron; (hexa-Fig. 3. Peritoneal equilibrium test (PET) results. D/D0 glucose and
gon) Group C, IFC 1 1 mg/L iron; (square) Group D, NC 1 normalD/P urea after one hour at 0, 6, and 12 weeks. D/D0 and D/P are
dialysis; (triangle) Group F, NC 1 2 mg/L iron. *P , 0.05 (A vs. D);defined in the text. Symbols are: (circle) Group A, IFC 1 normal
#P , 0.05 (A vs. B); **P , 0.001 (A vs. C); xP , 0.05 (B vs. D); yP ,dialysis; (inverted triangle) Group B, IFC 1 2 mg/L iron; (hexagon)
0.05 (C vs. D).Group C, IFC 1 1 mg/L iron; (square) Group D, NC 1 normal dialysis;
(triangle) Group F, NC 1 2 mg/L iron.
80 and 110 g, and the serum sample taken at that time was
nificant differences seen between Groups B and C when not adequate for the measurement. The measurements
compared with Group D at six weeks, but no significance were done at baseline, 6 weeks, and 12 weeks. At baseline,
was seen at 12 weeks. There was no significance seen be-
significant differences were seen between the iron-defi-
tween Groups B and C at baseline, 6 weeks, and 12 weeks.
cient group and the group on normal chow. There wereThere were significant differences between Group N and
no significant differences in the Groups A through C atall of the other groups at 12 weeks.
baseline. At 6 and 12 weeks, significant differences were
seen between the rats dialyzed with iron dextran as com-Peritoneal equilibrium test
pared with the dialysis control (A) in the iron-deficientChanges in D/D0 glucose over time are shown in Fig-
group. There were significant differences between theure 3. A tendency for D/D0 glucose to decrease over
iron-deficient rats dialyzed with iron dextran as comparedtime was noted in all the dialysis groups. There were
with rats on normal chow and dialysis (D) at 6 weeks, butno significant differences seen between the groups at
this significance did not hold at 12 weeks. The iron-defi-baseline 6 and 12 weeks. D/D0 glucose ratio at baseline
cient rats dialyzed with iron dextran 2 mg/L showed anwere 0.41 6 0.06, 0.42 6 0.05, 0.39 6 0.03, 0.40 6 0.05,
increase from 27.41 to 115, while the rats dialyzed withand 0.43 6 0.08 at six weeks; 0.35 6 0.02, 0.32 6 0.07,
1 mg/L showed an increase from 21 to 94. In general, iron-0.37 6 0.08, 0.40 6 0.03, and 0.39 6 0.04 at 12 weeks;
deficient rats showed an increase in serum iron whenand 0.24 6 0.03, 0.29 6 0.08, 0.24 6 0.04, 0.25 6 0.06,
supplemented with intraperitoneal iron dextran.and 0.26 6 0.03 in Groups A through D and F.
Changes in D/P urea are shown in Figure 3. A tendency
TIBCfor D/P urea to increase over time was noticed in all of
Changes in TIBC are shown in Figure 5. At baseline,the dialysis groups. The statistical analysis showed no
significant differences were seen between the iron-defi-significance at baseline, 6 weeks, and 12 weeks in all of
cient groups as compared with the groups on normalthe groups. The D/P urea ratio at baseline was 0.82 6
chow. There were no differences seen between Groups0.06, 0.80 6 0.03, 0.89 6 0.09, 0.90 6 0.04, and 0.88 6
A through C of the iron-deficient group at baseline. At0.08 at six weeks, 0.92 6 0.03, 0.93 6 0.08, 0.91 6 0.03,
6 and 12 weeks, significant differences were seen between0.92 6 0.09, and 0.91 6 0.05 at 12 weeks, 0.95 6 0.03,
the iron-deficient groups on iron dextran supplementa-0.95 6 0.06, 0.93 6 0.08, 0.94 6 0.01, and 0.95 6 0.06 in
tion (B and C) and iron-deficient group on dialysis (A)Groups A through D and F.
without iron dextran. At six weeks, significant differ-
Serum iron ences were seen between the iron-deficient groups on
iron supplementation when compared with the group onChanges in serum iron are shown in Figure 4. Serum
normal chow and dialysis (D). At 12 weeks, significantiron measurement was not done at less than three weeks,
as the rats were only four weeks old weighing between differences were still seen between Groups C and D. No
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Table 3. Findings in the peritoneal cavity during termination
(12 weeks)
Catheter Mesentery Thickness of
adhesions retractions mesentary
Slight 2
Group A (N 5 12) 5 5 Moderate 1
Severe 2
Slight 2
Group B (N 5 12) 5 4 Moderate 2
Severe 1
Slight 2
Group C (N 5 9) 4 3 Moderate 2
Severe 1
Slight 1
Group D (N 5 10) 4 4 Moderate 1
Severe 2
Slight 2
Group F (N 5 11) 5 5 Moderate 2Fig. 5. Changes in total iron binding capacity (TIBC) over time. Abbre-
Severe 1viations are: IFC, iron-deficient chow; NC, normal chow. Symbols are:
(circle) Group A, IFC 1 normal dialysis; (inverted triangle) Group B, N is the number of animals at the end of the study.
IFC 1 2 mg/L iron; (hexagon) Group C, IFC 1 1 mg/L iron; (square) Abbreviations are: IFC, iron-free chow; NC, normal chow. Groups are defined
Group D, NC 1 normal dialysis; (triangle) Group F, NC 1 2 mg/L as: Group A, IFC 1 normal dialysis; Group B, IFC 1 2 mg/L iron; Group C,
IFC 1 1 mg/L iron; Group D, NC 1 normal dialysis; Group F, NC 1 2 mg/Liron. #P , 0.001 (A vs. B); **P , 0.001 (A vs. C) at 6 and 12 weeks;
iron.*P , 0.001 (B vs. D) at 12 weeks; ‡P , 0.001 (B vs. D) at baseline
and at 6 weeks; †P , 0.001 (C vs. D) at baseline, 6 weeks, and 12
weeks.
DISCUSSION
Intraperitoneal iron supplementation was used moresignificant differences were seen between Groups B and
than 30 years ago to substitute blood losses during opera-D at 12 weeks. TIBC decreased from was 804.42 6 52.76
tive procedures or to treat iron-deficient patients withoutto 546.83 6 77.50 in Group B and 799.10 6 112.99 to
renal insufficiency [33, 34]. The use of intraperitoneal733.89 6 75.69 in Group C. TIBC increased from 806.25 6
route for iron delivery seems very attractive because of51.63 to 998 6 27.05 in Group A. The iron-deficient rats
noncompliance and gastrointestinal side effects of oraldialyzed with iron showed a decrease in TIBC over time.
iron [35, 36], and the risks and the inconveniences of the
Peritonitis intramuscular and the intravenous routes. The intraperi-
toneal route has been used for iron studies for severalThe peritonitis incidence was 0.11/animal/month in
years in guinea pig [17], rabbits, and rat models [37, 38].Group A, 0.13/animal/month in Group B, 0.12/animal/
In our previous studies in the rat model of peritonealmonth in Group C, 0.10/animal/month in Group D, and
dialysis, we have shown that there is a 70% absorption0.13/animal/month in Group F. There were no significant
rate of iron from the peritoneal cavity after a six-hourdifferences in the rate of peritonitis between the groups.
dwell [25, 26] and the absence of toxicity in intraperito-
Gross morphology during termination neal iron dextran administration (concentrations of 0.5,
0.25, and 0.125 mg/L) [28].During termination, no signs of iron deposition were
Iron dextran contains a ferric compound with dextranfound on gross inspection. The presence of iron in con-
that has a molecular weight of 160 to 180 kD. Leypoldtcentrations of 2 and 1 mg/L did not appear to cause any
et al have demonstrated that the transport of macromole-alteration in the retraction of the mesentery, degree of
cules (.40,000) is asymmetrical and occurs through themesentery thickness, and catheter adhesions when com-
lymphatics [39]. Flessner, Dedrick, and Reynolds suggestpared with the dialysis control groups (Table 3).
that transport of macromolecules (for example, IgG)Samples from the liver, abdominal wall, kidneys,
occurs directly into the surrounding tissue interstitialspleen diaphragm, and mesentery were analyzed. Prus-
space as a result of hydrostatic pressure driven convec-sian blue staining was done and did not reveal any iron
tion and diffusion. The route of transport of iron dextrandeposits in either the control or the study groups. The
is probably by both lymphatics and direct transport intosubmesothelial space was assessed by measuring the
the surrounding tissues; however, further evaluation isthickness of the connective tissue between the parietal
required [40, 41].peritoneum and the muscle layer of the abdominal wall.
The results suggest that intraperitoneal iron dextranThe measurements are given in Table 4. The results
supplementation given in the dose of 1 and 2 mg/L forrevealed no significant differences between the dialysis
a period of 12 weeks is sufficient to replenish the irongroups, but there were significant differences between
the control group and the dialysis groups (P , 0.05). stores in iron-deficient rats. A marked increase in serum
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Table 4. Findings among dialysis groups and the tissue control sumed per day was similar in both of the groups. The
groups (P , 0.05)
rats on iron dextran seemed to improve and move better
Group Thickness of the submesothelial layer lm toward the end of the study.
Group A 91618.50 Among nonuremic subjects, the body iron supply is
Group B 98.6621.23 tightly conserved, and iron deficiency usually develops only
Group C 99.1630.11
when chronic blood loss occurs. In patients with ESRD,Group D 95.4628.36
Group F 98.6626.22 iron deficiency occurs more frequently because of exter-
Group E 31.362.04 nal losses of iron, decreased availability of body storage
Group N 29.1618.66
iron, and a deficit in intestinal iron absorption. Moreover,
Groups are defined as: IFC, iron-free chow; NC, normal chow; Group A, the anemia of uremia is primarily caused by the inabilityIFC 1 normal dialysis; Group B, IFC 1 2 mg/L iron; Group C, IFC 1 1 mg/L
iron; Group D, NC 1 normal dialysis; Group F, NC 1 2 mg/L iron; Group E, of diseased kidneys to secrete adequate quantities of
IFC 1 no dialysis or catheter; Group N, NC 1 no dialysis or catheter. EPO [15, 42]. The present study was done on nonuremic
rats. In the case of uremic rats, there may be decreased
iron absorption and a sequestration of iron in storage
tissues with a decreased availability to erythropoieticiron and hematocrit levels and a corresponding decrease
in TIBC were seen after the supplementation with iron tissue. The concentration of iron required to correct the
anemia may be greater than in the present study. Thedextran. In addition, this supplementation resulted in
additional weight gain. Park et al have shown a decrease usage of intraperitoneal iron in conjunction with EPO
in iron-deficient uremic rats needs further evaluation.in serum iron levels at three months and an increase at
six months in rats supplemented with 2 mg/L iron [27]. Peritoneal injury can cause mesothelial denudation
inducing fibrosis of the submesothelial space in the pres-They have attributed this drop in serum iron levels at
three months to blood sampling by cardiac puncture. In ence of bioincompatible solution. The mesothelial cell
integrity can be re-established, but submesothelial fibrosisthe present study, similar findings are seen in Group
F at 12 weeks. In contrast, iron-deficient rats on iron results in irreversible damage to organ structure. The re-
sults showed an increase of thickness in the dialysis groupssupplementation demonstrated a marked increase in se-
rum iron at 12 weeks. Further studies are needed to as compared with the nondialysis groups. The thickness
of the submesothelial area was not different in the group,evaluate whether an iron-deficient state leads to greater
absorption from the peritoneal cavity. There was a slight which was given iron dextran as compared with the dial-
ysis control groups, suggesting that iron dextran adminis-increase in hematocrit in group A with a corresponding
decrease in serum iron. The pre-existing iron stores and tration did not induce any fibrotic changes that were
different than those induced by normal dialysis The his-trace amounts of iron present in the iron-free chow must
have been adequate to support this level of erythropoie- tologic study using Prussian blue staining showed no iron
deposition, and the differences between the groups weresis. Furthermore, in rats, the hematocrit continues to
increase throughout life and does not stabilize at a cer- not significant in terms of gross inspection findings.
The peritonitis rates were similar in all of the groups,tain point.
Dialysis in rats seems to cause a stress, which is re- and there were no significant differences. Martin, Jandl,
and Finland have worked on enhancement of bacterialflected by a lesser weight gain when compared with tissue
controls. This may be due to peritonitis, antibiotics, and infections in rats by the administration of intraperitoneal
iron, and they suggest that the pathogenicity of bacteriamanipulation during dialysis or the stress of dialysis itself.
The iron-deficient rats seemed to develop pruritus that is related directly to the availability of intraperitoneal
iron [44]. They have shown that iron 1 mg given intraperi-was noticed when the rats were constantly scratching
themselves. Because of this scratching, the rats devel- toneally has a 50% lethal dose of K. pneumoniae of 107.6.
In the present study, the concentration of iron used wasoped skin lesions. These skin lesions developed close to
the exit site of the catheters and on the back of the rats. 0.025 and 0.050 mg/rat/dialysis. The dose of iron was sub-
stantially lower as compared with the dose of iron used byThese lesions developed approximately one to two weeks
after the baseline PET was conducted. The rats were on Martin et al. As the rats in the current study were given
antibiotic coverage throughout the study period, this mayiron-deficient chow for a period of four to five weeks.
An important observation was that all the lesions healed have prevented peritonitis. However, further studies with-
out the coverage of antibiotics are required to determineon application of a local steroid ointment, but the lesions
healed in much lesser time in the iron-deficient rats on peritonitis rates in rats with intraperitoneal iron [43, 44].
In our previous studies, we have shown that in rats thatintraperitoneal iron dextran. They healed in about two
weeks of time. The lesions in the rats not on iron dextran were neither catheterized nor dialyzed, there were no
changes in D/P and D/D0 over time [45]. In the presenttook about six weeks to heal completely. The iron-defi-
cient rats seemed to move around sluggishly as compared study, the membrane function tests showed that the
changes that took place over time were similar in all thewith the rats on normal diet. The amount of diet con-
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tin with oral iron in peritoneal dialysis and hemodialysis patients,dialysis groups. They were characterized by an increase
in Advances in Peritoneal Dialysis, edited by Khanna R, Nolph
in D/P over time and a decrease in D/D0 over time. KD, Prowant BF, et al, Toronto, Peritoneal Dialysis Publications
9:177–180, 1993These results show that there is a higher permeability
17. Granolleras C, Oules R, Branger B, et al: Iron supplementationto small solutes after long-term peritoneal dialysis. These
of hemodialysis patients receiving recombinant human erythropoi-
results reflect the effects of bioincompatibility of the etin therapy, in Erythropoietin: Molecular Physiology and Clinical
Applications, edited by Bauer C, Koch KM, Stigalla P, et al,solutions on the peritoneal membrane, which is also seen
New York, Marcel Dekker, 1993, pp 211–218in long-term PD patients [46].
18. Suh H, Wadhwa NK: Iron dextran treatment in peritoneal dialysis
We conclude that intraperitoneal iron dextran supple- patients on erythropoietin, in Advances in Peritoneal Dialysis (vol
8), edited by Khanna R, Nolph KD, Prowant BF, et al, Toronto,mentation in rats is an acceptable method for main-
Peritoneal Dialysis Publications, 1992, pp 464–466taining a positive iron balance in iron-deficient condi-
19. Domoto DT, Martin KJ: Failure of CAPD patients to respond to
tions. We show an increase in hematocrit and serum iron an oral iron absorption test, in Advances in Peritoneal Dialysis
(vol 8), edited by Khanna R, Nolph KD, Prowant BF, et al,and a concurrent decrease in TIBC with the administra-
Toronto, Peritoneal Dialysis Publications, 1992, pp 102–104tion of intraperitoneal iron dextran. Furthermore, this
20. Fishbane S, Ungureaunu VD, Maesaka JK, et al: Safety of IV
administration does not cause any adverse affects to the iron dextran in hemodialysis patients. Am J Kidney Dis 28:529–534,
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21. Michelson E: Anaphylactoid reaction to dextran. N Engl J Medother animal model (guinea pig, rabbit, etc.) to support
278:552, 1968
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